Trends in Utilization of Urate ‐Lowering Therapies Following the FDA’s Boxed Warning to Febuxostat in the U.S.

AbstractGout is the most common inflammatory arthritis affecting nearly 4% of adults (9.2 millions) in the U.S. Initiation of urate ‐lowering therapy (ULT) is strongly recommended for all patients with tophaceous gout, radiographic damage, or frequent gout flares. While allopurinol is the first‐line ULT, some patients do not tolerate or adequately respond to allopurinol and require a different ULT such as febuxostat. At the time of approval of febuxostat in February 2009, the U.S. Food and Drug Administration (FDA) mandated a post‐marketing cardiovascular safety trial (the CARES trial) to address concerns related to cardiovascular risk raised during premarketing trials.

Source: Arthritis and Rheumatology - October 7, 2020 Category: Rheumatology Authors: Seoyoung C Kim, Tuhina Neogi, Erin Kim, Joyce Lii, Rishi J Desai Tags: LETTER TO THE EDITOR Source Type: research